Bifidobacterium bifidum Bbifi-1 and application thereof

By using Bifidobacter bifidobacterium Bbifi-1 to improve intestinal flora balance and reduce inflammatory response, the shortcomings of chemoradiotherapy-related diarrhea treatment in the prior art were solved, and a safe and efficient diarrhea improvement effect was achieved.

CN118995463APending Publication Date: 2024-11-22SICHUAN ANAEROBIC BIOTECHNOLOGY CO LTD
View PDF 0 Cites 5 Cited by

Patent Information

Application Number
CN202410604905.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art lacks effective treatment methods for chemoradiotherapy-related diarrhea. The existing probiotic products have a single effect, have side effects in long-term use, and have failed to effectively improve intestinal flora disorders and inflammatory responses.

Method used

Provide a Bifidobacter bifidobacterium Bbifi-1 and its preparation method, which has antioxidant ability and can inhibit a variety of pathogenic bacteria and proinflammatory factors, and is used to treat chemoradiotherapy-related diarrhea, and improves the balance of intestinal flora and Reduce inflammatory response.

Benefits of technology

It significantly improves diarrhea caused by chemoradiation and has good safety, does not cause gastrointestinal peristalsis side effects, can be taken for a long time, and has antioxidant and free radical scavenging functions, achieving the effect comparable to the chemical drug loperamide.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995463A_ABST
    Figure CN118995463A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of microbial medicines, and particularly relates to bifidobacterium bifidum with the microbial preservation number of CCTCC NO: M2023349 and application of the bifidobacterium bifidum to prevention or treatment of tumor treatment related diarrhea. The genome of the bifidobacterium bifidum provided by the invention is free of virulence factor genes, and is free of hemolysis, namely good in safety; the strain can tolerate gastric acid and can survive in the gastrointestinal tract of a human body; in addition, the strain can also inhibit various pathogenic bacteria, inhibit expression of proinflammatory factors and remarkably improve diarrhea caused by radiotherapy and / or chemotherapy, and a better treatment scheme is provided for tumor patients needing long-term treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of microbial drugs and relates to a Bifidobacterium bifidum Bbifi-1 and an application thereof, and specifically relates to a Bifidobacterium bifidum Bbifi-1 and an application thereof in preventing or treating anti-tumor therapy-associated diarrhea. Background Art

[0002] Diarrhea refers to bowel movements that are significantly more frequent than usual, and the stool is often watery or mushy. Some cancer treatments can cause diarrhea. This includes some chemotherapy drugs, targeted anti-cancer treatments, and radiotherapy to the abdomen or pelvic area. Diarrhea caused by anti-tumor treatment is a common gastrointestinal toxicity during tumor treatment. Mild diarrhea can reduce the patient's quality of life, and frequent severe diarrhea may cause dehydration, infection, shock, or even death. Therefore, severe diarrhea can lead to the suspension or termination of treatment, greatly affecting the long-term outcome of tumor treatment and is potentially fatal.

[0003] Chemotherapy-induced diarrhea (CID) can be caused by a variety of chemotherapy drugs, but mainly 5-fluorouracil (5-FU) and irinotecan (CPT-11), accounting for 80% of all cases. In addition, as more and more abdominal and pelvic tumors are treated with radiotherapy, radiotherapy-induced diarrhea is becoming more common. Radiation enteritis (RE) is a common complication after the normal intestinal tissue around the tumor is damaged by ionizing radiation during radiotherapy. It is a nonspecific inflammatory reaction, with radiation enteritis and radiation proctitis being the most common clinically. After receiving radiotherapy, 60% to 70% of patients will experience acute symptoms such as abdominal pain, diarrhea, and bloody stools, and 30% to 40% of patients will experience chronic diarrhea.

[0004] The mechanism of diarrhea caused by radiotherapy and chemotherapy has not been fully understood so far, and existing studies have shown that it is caused by multiple factors. These mainly include: changes in intestinal motility, oxidative damage, immune imbalance, inflammatory response, intestinal flora imbalance, bacterial or fungal infection, etc. At present, there is a lack of targeted drugs for the treatment of radiotherapy and chemotherapy-related diarrhea in clinical practice. All of them are symptomatic treatments with drugs such as opioids, somatostatin analogs, glucocorticoids, bile acid sequestrants, antibiotics, etc., but these drugs have a single mechanism of action and have large side effects when used for a long time. For example, opioids (loperamide, etc.) may cause the risk of paralytic ileus when used in large doses; somatostatin analogs (octreotide, etc.) may cause side effects such as gallstones, hyperglycemia, and impaired glucose tolerance; glucocorticoids may have systemic effects, increase the risk of infection, and aggravate viral or bacterial infections; bile acid sequestrants are suitable for diarrhea caused by bile acid malabsorption or excessive lipids, but they may cause gastrointestinal side effects such as abdominal distension, flatulence, and constipation.

[0005] The intestinal microecology system is the largest and most important microecology system in the body. Imbalance of intestinal microecology is closely related to the pathogenesis of many diseases. Symbiotic bacteria play an important role in intestinal homeostasis and play an important role in the integrity of intestinal barrier function. At present, there are probiotic products represented by bifidobacterium, lactobacillus, bacillus and Clostridium butyricum on the market that can relieve diarrhea symptoms, but such traditional probiotic products are not developed for anti-tumor treatment-related diarrhea. In order to play a therapeutic role in the complex mechanism of diarrhea, it is also urgent to develop probiotics that have multiple improvement effects on indicators such as diarrhea, pathology, inflammation, and intestinal barrier repair, in order to provide patients with a new and targeted treatment option. Bifidobacterium bifidum belongs to probiotics, and there are many related studies, which have received certain attention. Patent CN112694992B provides a strain of Bifidobacterium bifidum that can relieve diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Patent CN114127258A provides a strain of Bifidobacterium bifidum that can treat functional gastrointestinal diseases such as irritable bowel syndrome. Patent CN113234619B provides a strain of Bifidobacterium bifidum that can relieve acute intestinal damage. In general, the prior art has shown that Bifidobacterium bifidum has potential benefits for human health, such as infectious diarrhea, functional gastrointestinal discomfort, etc. However, no studies have reported that a single strain of Bifidobacterium bifidum has a significant improvement effect on both radiotherapy and chemotherapy-related diarrhea, and also has multiple effects such as inhibiting pathogens and anti-oxidation. Summary of the invention

[0006] The present invention aims at the deficiencies of existing clinical treatments and provides a probiotic for treating diarrhea, especially radiotherapy and chemotherapy-related diarrhea. The probiotic provided by the present invention has good safety, antioxidant capacity, can inhibit a variety of pathogenic bacteria and pro-inflammatory factors, and significantly improves diarrhea caused by radiotherapy and chemotherapy.

[0007] The first aspect of the present invention provides a biomaterial, which is selected from the following M1, M2, M3 and M4; M1: Bifidobacterium bifidum with a microbial preservation number of CCTCC NO: M2023349 or a lysate thereof; M2: a progeny strain of Bifidobacterium bifidum with a microbial preservation number of CCTCC NO: M2023349 or a lysate thereof; M3: a cloned strain of Bifidobacterium bifidum with a microbial preservation number of CCTCC NO: M2023349 or a lysate thereof; M4: a pure culture of Bifidobacterium bifidum with a microbial preservation number of CCTCC NO: M2023349 or a lysate thereof.

[0008] A second aspect of the present invention provides a method for culturing Bifidobacterium bifidum, the method comprising: inoculating Bifidobacterium bifidum with a microbiological deposit number of CCTCC NO: M2023349, a progeny strain of Bifidobacterium bifidum with a microbiological deposit number of CCTCC NO: M2023349, a cloned strain of Bifidobacterium bifidum with a microbiological deposit number of CCTCC NO: M2023349, or a pure culture of Bifidobacterium bifidum with a microbiological deposit number of CCTCC NO: M2023349 into a culture medium, performing proliferation culture, and obtaining proliferated Bifidobacterium bifidum.

[0009] The third aspect of the present invention provides a composition, wherein the composition uses the biomaterial described in the first aspect of the present invention as an active material.

[0010] In some embodiments, the composition further contains an auxiliary material.

[0011] In some embodiments, the excipient is selected from any one of the following materials: a pharmaceutically acceptable carrier or excipient; a bacterial culture medium; a lyophilization protectant; an acceptable material in health products; an acceptable material in cosmetics; or an acceptable material in food.

[0012] The fourth aspect of the present invention provides the use of the biomaterial described in the first aspect of the present invention or the composition described in the third aspect of the present invention in the preparation of a product for use alone or in combination with other microbial preparations and / or drugs to improve the health of a subject; the improving the health of the subject is selected from: treating, preventing and / or alleviating diarrhea caused by chemotherapy; treating, preventing and / or alleviating side effects caused by radiotherapy; inhibiting the proliferation of any one, any two, any three, any four, any five, any six, any seven or eight of Staphylococcus aureus, Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile in the body cavity of the subject; treating, preventing and / or Alleviate tissue damage, disease or sub-health condition caused by any one, any two, any three, any four, any five, any six, any seven or eight of Staphylococcus aureus, Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile; treat, prevent and / or alleviate diseases or sub-health conditions caused by Propionibacterium acnes; treat, prevent and / or alleviate acne; treat, prevent and / or alleviate tissue damage, disease or sub-health condition caused by increased expression of any one, any two or three of IFN-γ, TNF-α and IL-6; scavenge DPPH free radicals and / or ABTS free radicals; improve the antioxidant capacity in the intestine of the subject; improve cellular lipid accumulation.

[0013] In some embodiments, the product is a pharmaceutical product.

[0014] In some embodiments, the product is a health product.

[0015] In some embodiments, the product is a food product.

[0016] In some embodiments, the product is a cosmetic.

[0017] In some embodiments, the subject is selected from a human and a mouse.

[0018] In some embodiments, the side effect caused by the radiotherapy is radiation enteritis.

[0019] In some embodiments, the chemotherapy drug is selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.

[0020] In some embodiments, the chemotherapy drug is selected from doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, cisplatin, carboplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, 5-fluorouracil, and irinotecan.

[0021] The Bifidobacterium bifidum described in the present invention also has the following identification characteristics: no virulence factors; no hemolysis; anti-oxidation and free radical scavenging capabilities; gastric acid resistance; inhibition of the expression of pro-inflammatory factors TNF-α and IL-6; antibacterial capabilities against one or more of Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile; and the ability to prevent, improve, reduce or alleviate radiotherapy and / or chemotherapy-related diarrhea.

[0022] The beneficial effects of the present invention include: 1. The Bifidobacterium bifidum Bbifi-1 of the present invention has no toxic factors, is non-hemolytic, and has good safety; 2. It has antioxidant function and can reduce the damage caused by oxidative stress caused by radiotherapy and chemotherapy; 3. It has an inhibitory effect on a variety of pathogenic bacteria, can regulate intestinal flora, and inhibit the growth of pathogenic bacteria; 4. It inhibits the expression of pro-inflammatory factors and reduces intestinal inflammatory reactions; 5. The Bifidobacterium bifidum Bbifi-1 of the present invention has an improvement effect on diarrhea caused by radiotherapy and chemotherapy that is equivalent to that of the chemical drug loperamide, and does not have the side effect of inhibiting gastrointestinal motility, which can meet the needs of tumor patients for long-term use; 6. The Bifidobacterium bifidum Bbifi-1 lysate of the present invention has the functions of scavenging free radicals and controlling the oil secretion of skin cells, thereby achieving the effects of anti-aging and oil control. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a front view photo of the colony morphology of Bifidobacterium bifidum Bbifi-1.

[0024] Figure 2 The results of in vitro antioxidant tests of each experimental group are shown.

[0025] Figure 3 The results of the antibacterial test of Bifidobacterium bifidum Bbifi-1 against various pathogenic bacteria are shown.

[0026] Figure 4 The results of the in vitro inhibition test of the inflammatory factor TNF-α in each experimental group are shown.

[0027] Figure 5 The figure shows the therapeutic effect of each experimental group on mice with diarrhea caused by 5-fluorouracil. A is the diarrhea score curve of each group from day 1 to day 9, and B is the total diarrhea score of each group.

[0028] Figure 6 The figure shows the therapeutic effect of each experimental group on mice with diarrhea caused by 5-fluorouracil. A is the diarrhea score curve of each group from day 1 to day 7, and B is the total diarrhea score of each group.

[0029] Figure 7 The figures show the therapeutic effects of each experimental group on mice with diarrhea caused by radiation enteritis. A is the diarrhea score curve of each group from day 1 to day 9, and B is the total diarrhea score of each group.

[0030] Figure 8 The results of the total antioxidant test of Bifidobacterium bifidum Bbifi-1 lysate are shown.

[0031] Fig. 9 The results of DPPH clearance of Bifidobacterium bifidum Bbifi-1 lysate are shown.

[0032] Fig.10 The results of ABTS clearance of Bifidobacterium bifidum Bbifi-1 lysate are shown.

[0033] Fig.11 The figures show the antibacterial test results of Bifidobacterium bifidum Bbifi-1 lysate, A is the antibacterial result against Staphylococcus aureus, and B is the antibacterial result against Propionibacterium acnes.

[0034] Fig.12 The results show that the lysate of Bifidobacterium bifidum Bbifi-1 inhibited the expression of IL-6 in inflammatory cells.

[0035] Fig.13 The results show that Bifidobacterium bifidum Bbifi-1 inhibits cellular lipid secretion. DETAILED DESCRIPTION

[0036] To make the purpose, technical solution and advantages of the present invention clearer, the embodiments of the present invention will be described in further detail below in conjunction with the accompanying drawings. Unless otherwise specified, the terms used herein have the common meanings in the biomedical field.

[0037] The specific temperature parameters in the present invention, unless otherwise specified, should be understood as constant temperature treatment, and are allowed to fluctuate within a certain temperature range, such as within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C.

[0038] Chemotherapy refers to the use of drugs to kill tumor cells to achieve treatment goals. It is the main means of treating tumors besides surgery and radiotherapy.

[0039] Chemotherapy-related diarrhea refers to diarrhea caused by gastrointestinal toxicity of chemotherapy drugs, including but not limited to non-targeted small molecule drugs, targeted small molecule drugs, biological macromolecule drugs, nucleic acid drugs and cell therapy drugs. Examples of these drugs include, but are not limited to, antibiotic chemotherapy drugs, such as doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin and their derivatives; paclitaxel chemotherapy drugs, such as paclitaxel, docetaxel, albumin-paclitaxel and their derivatives; platinum chemotherapy drugs, such as cisplatin, carboplatin, nedaplatin, oxaliplatin, lobaplatin and their derivatives; alkylating agent chemotherapy drugs, such as cyclophosphamide, nitrogen mustard, carmustine and their derivatives; camptothecin chemotherapy drugs, such as camptothecin, hydroxycamptothecin, topotecan, irinotecan and their derivatives; antimetabolite chemotherapy drugs, such as capecitabine, gemcitabine, methotrexate, fluorouracil, pemetrexed, cytarabine and their derivatives; targeted drugs, such as apatinib, axitinib, cabozantinib, sorafenib, sunitinib; anti-PD-1PD- / L1 antibodies, such as nivolumab and pembrolizumab.

[0040] Radiotherapy refers to a method of treating malignant tumors by using radiation such as α, β, γ rays produced by radioactive isotopes and x-rays, electron beams, proton beams and other particle beams produced by various x-ray therapy machines or accelerators.

[0041] Radiation therapy-related diarrhea refers to diarrhea caused by the use of radiation therapy methods to treat tumors. The radiation therapy methods include but are not limited to conventional radiotherapy, stereotactic radiotherapy, three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, image-guided radiotherapy, volumetric arc-modulated radiotherapy, proton radiotherapy, etc.

[0042] Several or more refers to two or more types that are integers, such as two, three, four, five, six, seven...etc.

[0043] The Bifidobacterium bifidum of the present invention may be a live bacterium, or an inactivated bacterium, or a pure culture, lysate, culture fluid (such as supernatant) of the bacterium, or a component extracted from the culture.

[0044] In some embodiments, Bifidobacterium bifidum is a live bacterium, an inactivated bacterium, or a combination thereof (i.e., a combination of live bacteria and inactivated bacteria). The inactivated bacteria may be an inactivated bacterium with a complete morphological structure, an inactivated bacterium with an incomplete morphological structure, or a combination thereof. The Bifidobacterium bifidum of the present invention includes a strain Bifidobacterium bifidum Bbifi-1 having a deposit number of CCTCC NO: M 2023349, and a progeny strain thereof or a strain (clone strain) obtained by culturing the original strain. The progeny strain and the clone strain have similar activity to Bbifi-1.

[0045] The present invention provides a pharmaceutical composition, which contains a therapeutically or prophylactically effective amount of Bifidobacterium bifidum Bbifi-1 and a pharmaceutically acceptable carrier and / or excipient. The pharmaceutical composition is used for the treatment and / or prevention of diarrhea caused by anti-tumor therapy. Further, the pharmaceutical composition is used for the treatment and / or prevention of radiotherapy and / or chemotherapy-related diarrhea.

[0046] The therapeutically effective amount or prophylactically effective amount is an amount that can achieve the desired therapeutic or prophylactic effect clinically. In some embodiments, the therapeutically effective amount does not induce or cause undesirable side effects. In some embodiments, the therapeutically effective amount induces or causes side effects, but only causes side effects that are acceptable to the treating clinician in view of the patient's condition. In some embodiments, a single dose or a single effective amount contains 10 2 ~10 15 CFU, 10 3 ~10 14 CFU, 10 4 ~10 13 CFU, 10 5 ~10 12 CFU, 10 6 ~10 12 CFU of Bifidobacterium bifidum.

[0047] A pharmaceutically acceptable carrier refers to a pharmaceutical carrier that does not cause significant stimulation to a subject and does not eliminate the biological activity and characteristics of the probiotics administered. A pharmaceutically acceptable carrier can enhance or stabilize the composition, or can be used to promote the preparation of the composition. A pharmaceutically acceptable carrier may include solvents, dispersion media, coatings, surfactants, antioxidants, isotonic agents, absorption delay agents, salts, drug stabilizers, binding agents, excipients, disintegrants, lubricants, sweeteners, flavoring agents, dyes, etc. and combinations thereof, as known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, the 18th edition Mack Printing Company, 1990, pages 1289-1329). Unless conventional carriers are incompatible with active ingredients, it is considered to be used in therapeutic or pharmaceutical compositions. The carrier may be selected to minimize adverse side effects of the subject and / or minimize the inactivation of the active ingredient.

[0048] Excipients refer to substances added to pharmaceutical compositions to give the drug a certain shape or concentration, such as sterile water, physiological saline, polyalkylene glycols (such as polyethylene glycol), vegetable oils or hydrogenated naphthalene, calcium bicarbonate, calcium phosphate, various sugars, various types of starch, cellulose derivatives, gelatin, etc.

[0049] The pharmaceutical composition of the present invention may further contain a second beneficial active ingredient, such as another probiotic, prebiotic or drug with antidiarrhea function, and the prebiotic helps regulate the intestinal environment by promoting the growth of probiotics in the intestine, thereby indirectly playing an antidiarrhea effect. Examples of the second beneficial active ingredient include, but are not limited to, Bacillus licheniformis, Bifidobacterium, Clostridium butyricum, oligofructose, galacto-oligosaccharide, isomaltooligosaccharide, oligoxylose, oligomannose, inulin, stachyose, soybean oligosaccharide, beta glucan, oligolactose, etc. In some embodiments, the dosage form of the pharmaceutical composition is tablets, capsules, granules, solutions, suspensions or powders, etc.

[0050] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work should fall within the scope of protection of the present invention.

[0051] The culture medium used in the following examples is prepared as follows. Those not specifically mentioned can be obtained commercially or prepared by conventional experimental methods:

[0052] Preparation of YCFA liquid culture medium: weigh 10.0 g of casein peptone, 2.5 g of yeast extract, 0.45 mL of MgSO4·7H2O (10% mother liquor), 0.45 mL of CaCl2 (10% mother liquor), 10 mL of TE141, 0.45 g of K2HPO4, 0.45 g of KH2PO4, 0.90 g of NaCl, and 3.2 mL of VFA-mix, dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, store in a cool and dry place for later use.

[0053] Preparation of TE141: Weigh 1.50 g of nitrilotriacetic acid and add it to 200 mL of pure water, add an appropriate amount of NaOH until the solution becomes clear, then add 800 mL of water, adjust the pH value to 5.5 with 50% HCl, then weigh 3.00 g of MgSO4·7H2O, 0.50 g of MnSO4·H2O, 1.00 g of NaCl, 0.10 g of FeSO4·7H2O, 0.18 g of CoSO4·7H2O, 0.10 g of CaCl2·2H2O, 0.18 g of ZnSO4·7H2O, 0.006 g of CuSO4·5H2O, 0.02 g of KAl(SO4)2·12H2O, 0.01 g of H3BO3, 0.01 g of Na2MoO4·2H2O, and 0.01 g of NiCl2·6H2O. 0.03 g, 0.03 mL (10 mg / mL stock solution) of Na2SeO3·5H2O, and 0.03 mL (10 mg / mL stock solution) of Na2WO4·2H2O were added to the above test solution. Stir continuously during the addition process to keep the solution clear for later use.

[0054] Preparation of VFA-mix: Measure 90 mL of acetic acid, 30 mL of propionic acid, 10 mL of n-valeric acid, 10 mL of isobutyric acid, and 10 mL of butyric acid, mix well for later use, and adjust to neutrality with 5 M NaOH before use.

[0055] Preparation of triple-mixed liquid culture medium (BHI+MRS+modified GAM): weigh 19.25 g of BHI broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8297-5), 13.5 g of MRS broth powder (Guangdong Huankai Biotechnology Co., Ltd., 027312), and 15 g of modified GAM broth powder (Qingdao Haibo Biotechnology Co., Ltd., HB8518-3), dissolve in 1 L of distilled water, deoxygenate with N2 replacement and package, sterilize at 121°C for 30 min, and store in a cool and dry place.

[0056] Preparation of three-mix solid culture medium (BHI+MRS+modified GAM): Add 5 g of agar powder to the three-mix liquid culture medium, and the other steps are the same.

[0057] Preparation of the second mixed culture medium (BHI+MRS): Weigh 19.25 g of BHI broth powder, 27.0 g of MRS broth powder, and 0.5 g of cysteine ​​hydrochloride monohydrate (Emeishan Longteng Biotechnology Co., Ltd.), dissolve in 1 L of distilled water, deoxygenate and package, sterilize at 121°C for 15 min, and store in a cool and dry place.

[0058] Preparation of BF839 medium: weigh 6.0 g potato extract powder (Beijing Solebow Technology Co., Ltd., FA0270), 10.0 g polyvalent peptone (Beijing Solebow Technology Co., Ltd., P8950-250), Peptone (HB8277, Qingdao Hi-Tech Industrial Park Haibo Biotechnology Co., Ltd.), sodium thioglycolate (Shanghai Aladdin Biochemical Technology Co., Ltd., S105664-25G), yeast extract powder (Thermo Fisher Oxoid, LP0021B), glucose (50-99-7, Chengdu Kelong Chemical Co., Ltd.), sodium dihydrogen phosphate (7558-79-4, Chengdu Kelong Chemical Co., Ltd.), 4.0 g were dissolved in 1 L of distilled water, deoxygenated by N2 replacement, and packaged separately. Sterilize at 121 °C for 30 min and store in a cool and dry place.

[0059] Preparation of artificial gastric juice: adjust the pH of artificial gastric juice (Shanghai Yuanye Biotechnology Co., Ltd., R30387, containing 10 g / L pepsin) to 3.0, and continue to pass N2 for 1 hour. Sterilize with a 0.22 μm filter in an anaerobic glove box and set aside. Store at 4°C for no more than 30 days.

[0060] Preparation of anaerobic PBS: Weigh 0.27g of potassium dihydrogen phosphate, 1.42g of disodium hydrogen phosphate, 8g of sodium chloride, and 0.2g of potassium chloride, dissolve in 1L of distilled water, heat to boil, cool to room temperature, add 0.55g of cysteine ​​hydrochloride, stir to dissolve, adjust the pH to 6.5, install a quantitative dispenser and pass N2, heat to boiling, keep at a slight boiling state for 30min, cool and package into 400mL / bottle, sterilize at 121℃ high temperature and wet heat for 30min, store in a cool and dry place for later use.

[0061] GAM solid culture medium, TSB (Tryptone Soy Broth, Qingdao Haibo Biotechnology Co., Ltd., HB4114), and TSA (Tryptone Soy Agar, Qingdao Haibo Biotechnology Co., Ltd., HB4138) culture medium were prepared by weighing and dissolving according to the instructions, sterilizing with high temperature and wet heat at 121°C for 30 min, and storing in a cool and dry place.

[0062] Preparation of fermentation medium from bacterial powder: weigh 20g of anhydrous glucose, 40g of soy peptone, 5g of N-acetylglucosamine, 2g of potassium dihydrogen phosphate, 2g of disodium hydrogen phosphate, 0.1g of magnesium sulfate, 0.045g of manganese sulfate, 1mL of Tween 80, and 0.5g of monohydrated cysteine ​​hydrochloride, and dissolve them in 1L of purified water. Deoxygenate by N2 replacement, aliquot, sterilize at 121℃ for 15min, and store in a cool, dry place.

[0063] Example 1: Isolation and identification of Bifidobacterium bifidum Bbifi-1

[0064] The screening and separation method of Bifidobacterium bifidum Bbifi-1 is as follows:

[0065] Collect fresh fecal samples from healthy volunteers, add appropriate amount of oxygen-free PBS to resuspend and shake, and make sure the sample is fully resuspended. Under N2 protection, filter twice through gauze, and dispense the filtrate into 50mL centrifuge tubes. Centrifuge at 10000rpm for 20min and discard the supernatant. Add appropriate amount of oxygen-free PBS to resuspend the bacteria in the centrifuged precipitate, then add an equal volume of 50% oxygen-free glycerol aqueous solution to mix thoroughly, and dispense into 2mL screw cap tubes, 0.5mL each. After dispensing, vacuum the bag and store in a -80℃ refrigerator for later use.

[0066] During separation, take out one frozen sample tube, resuspend the thawed sample in anaerobic PBS at a volume ratio of 1:10 (tenfold dilution), vortex and shake for 5 minutes, transfer to the anaerobic glove box, take 0.5mL of bacterial suspension and shake in 4.5mL of anaerobic PBS to mix. Use the same tenfold dilution method as above to dilute the sample to 10 -6, take appropriate bacterial solution gradient and mix with YCFA liquid medium, then divide into 384-well plates and culture anaerobically at 37℃ for one week. Pick the bacterial solution from the growing wells for transfer. After 48 hours of culture, divide the bacterial solution into two parts. One part is detected by MALDI-TOF-MS to preliminarily classify the isolated strains. When it can be successfully classified, the corresponding other part is transferred to a 96-well plate again according to the mass spectrometry results. After 48 hours of culture, one plate is amplified for 16SrDNA sequence and sequenced by Beijing Qingke Biotechnology Co., Ltd. Chengdu Branch. The other plate is mixed with 50% glycerol aqueous solution at a volume ratio of 1:1 and stored temporarily for use after the PCR results are confirmed. The 16S rDNA sequencing results of several isolated strains were analyzed and compared with the NCBI nt library. The results showed that one of the isolated strains had the highest sequence similarity with a strain of Bifidobacterium bifidum (99.86%). Therefore, it was preliminarily identified as Bifidobacterium bifidum and named Bifidobacterium bifidum Bbifi-1 (Bbifi-1 for short). Its colony morphology on the three-mixed solid medium was white opaque circular colonies with a convex middle and a smooth and moist surface. The front photo is shown in Figure 1 .

[0067] The Bbifi-1 strain was submitted and deposited in the China Center for Type Culture Collection (CCTCC) on March 17, 2023. The strain preservation number is: CCTCC NO: M 2023349, the culture name is: Bifidobacteriumbifidum Bbifi-1, the Chinese classification name is: Bifidobacterium bifidum, and the English classification name is: Bifidobacteriumbifidum.

[0068] Example 2: Whole genome analysis of Bifidobacterium bifidum Bbifi-1

[0069] Bifidobacterium bifidum Bbifi-1 was inoculated into 5 mL of three-mixed liquid medium at a 2% inoculum, cultured to the late logarithmic growth stage, and the whole genome DNA of the strain was extracted. The whole genome was sequenced using the Illumina high-throughput sequencing platform NovaSeq 6000. After assembling and annotating the whole genome sequence, the protein sequence was entered into the Virulence Factor Databases (VFDB) for virulence factor analysis. The results showed that the bacteria did not have virulence factors. The average nucleotide similarity (Average Nucleotide Identity, ANI) was used to analyze the novelty of the strain. By searching in Genbank, 108 published Bifidobacterium bifidum complete genomes were found. By fastANI (v1.33) comparison, it was found that the two strains closest to the complete genome of Bifidobacterium bifidum Bbifi-1 of the present invention were GCA_003466395.1 (ANI = 99.01%) and GCA_003437945.1 (ANI = 99.00%), so Bifidobacterium bifidum Bbifi-1 can be considered as a new strain. The 16S rDNA sequence of Bifidobacterium bifidum Bbifi-1 is shown in the following sequence 1 (SEQ ID NO: 1).

[0070] The whole genome was annotated using emapper-2.1.9, and it was found that Bifidobacterium bifidum Bbifi-1 encodes one acetic acid-producing enzyme and one propionic acid-producing enzyme, whose amino acid sequences are shown in the following sequence 2 (SEQ ID NO: 2) and sequence 3 (SEQ ID NO: 3), respectively.

[0071] Sequence 1:

[0072]

[0073] sequence2:

[0074] MRKAKIVDTIGPSTESPEGITKLVEAGMDVARLNRSHGTPEDHLKVYNNVRAASKATGRNVAAMVDLQGPKIRCGWFKKNAEGEDKVQLEEGQEFIITTDDVEGDEHITSTTFKGLPGDPGDPILIDDGKVRLEVTKVEGNNVHTKVVVAGPVSSHKGINLPGVAVSLPALTEKDEADLRWAIRTGADIIAMSFVRFATDIDRAHEIMDEEGRRIPIVAKIEKPQALENLEDIVKTFD GVMAARGDMAVECPLEEVPLATKRIIELARQYAKPVIVATEVLGSMVHSPVPSRAEASDCANAVLDGADATMTSNETAVGEYPTETVATMSRISGFATEHGFDRIPELKNLDMSSTGAVSSAAVDLAEKLNAKAIVAYTQTGNTVHRVSRERPAAPIYGLTTNEHTYHWLALSWGTEAFLLDEDYHDKTRKDLMAFTDKVLKNAGKVSDGDKIVVLSSAQGEHAAGSTDTIYVHTVGAND

[0075] sequence3:

[0076] MTDTDQQITPADATIVSTGTGTKGPEERELPESLSNDMSLCLRILRDVLGEYDPQLLATFDTVRNYAVKASAEHFAGATADPHPDEDGLAKAVATIDAMNLHDAQLLARAFATYFHLANLSEENYRVSVLHQRENQVEDDEAVDPVNELTTAYHQLLTEMGPAKAKALLEKLEFHPVFTAHPTEARRKAVEGKIRRIAELLEENKRLGGSDKKENVRRLYNEIDALFRTSPIALKKPTPVEEADTILDIFDNTLFTTIPKVYHRFNDWLLGDKAGLEQPQCPAFFHPGSWIGSDRDGNPNVTAKVSRQVARKFSDHVIGALEEATRTVGRNLTMESETTPASAELKSLWSHQKEMSERLTDKAALISTKELHRAVMLVMADRLRYTIERDADLMYHSCDDFIADLQVVQRSLAEAGAKRSAYGPLQDLIWQAQTFGFHMVEMEFRQHSVVHARALEDIREHGLHGERGELQPMTHEVLDTFRALGAIQKRNGIKAARRYIISFTKSAQNVRDVYELNRLAFSHPEDVPVIDVIPLFEQLEDLQNCVNVLEEIVKIPEVQARLKATGNKMEVMLGYSDSSKDAGPTTATLALHSAESRIVAWAAKHDIDLTLFHGRGGAVGRGGGPANRAVLAQPKGSVNCRFKLTEQGEVIFARYGNPVLAIRHLESVAAATLLQSAPSVEKTNTEMTEKYAHMTEVLDNASHERFLDLLNTPDFAPWFSIVTPLTEVGLLPIGSRPAKRGLGAKSLDDLRTIPWVFSWAQARINLAAWYGLGSACEKFGDLDTLREAYEEWPLFSTFIDNIEMSLAKTDERIAKMYLALGDDENLSKKVLDEMKLTTKWVLKIVNDEWPLQHRHVLGQAIRIRSPYVDALSVTQVLALRSLRKKVDKEELSKSQQAGFIYLILCTVSGVAAGLQNTG

[0077] Example 3: Hemolysis test of Bifidobacterium bifidum Bbifi-1

[0078] The preserved Bifidobacterium bifidum Bbifi-1 was inoculated into 5mL of three-mixed liquid medium at a 2% inoculation amount, and anaerobically cultured at 37°C until the late logarithmic growth period to obtain an activated strain. 2mL of 2% fresh rabbit red blood cell suspension (Beijing Borsi Technology Co., Ltd.) and the bacterial suspension resuspended with 2mL of 0.9% sterile saline (Shandong Qidu Pharmaceutical Co., Ltd.) were tested by liquid contact method, with an equal volume of sterile water as a positive control (hemoglobin is released after red blood cells absorb water and burst), and an equal volume of sterile saline as a negative control. Three parallels were set for each group, and each sample was photographed after standing for 24 hours. The results showed that the negative control was not hemolytic, the positive control was hemolytic, and the Bifidobacterium bifidum Bbifi-1 bacterial suspension had no hemolytic phenomenon, which met the basic requirements for the safety of intestinal probiotics.

[0079] Example 4: Gastric juice resistance of Bifidobacterium bifidum Bbifi-1

[0080] Inoculate Bifidobacterium bifidum Bbifi-1 into 5mL of three-mixed liquid medium at a 2% inoculum amount and culture until the late logarithmic growth period. Take 1mL of the cultured bacterial solution and centrifuge (8000rpm, 5min), discard the supernatant and resuspend the bacteria with 1mL PBS and pH 3.0 artificial gastric juice respectively. After incubation at 37℃ for 3h, take an appropriate amount of bacterial suspension and dilute it 10 times with PBS. Take 50μL of the appropriate gradient bacterial suspension and mix it with 0.5% three-mixed solid medium, culture it anaerobically at 37℃ until a single colony grows and then count it. Experimental results: The number of viable bacteria of Bifidobacterium bifidum Bbifi-1 after incubation in PBS for 3h is (2.37±0.21)×10 8 CFU / mL, and the number of viable bacteria after treatment with pH 3.0 artificial gastric juice was (2.97±0.12)×10 8 CFU / mL, indicating that Bifidobacterium bifidum Bbifi-1 has good tolerance to pH 3.0 artificial gastric juice and has the basic property of being a probiotic without being digested in the intestine.

[0081] Example 5: Antioxidant experiment of Bifidobacterium bifidum Bbifi-1

[0082] After the preserved Bifidobacterium bifidum Bbifi-1 was activated, it was inoculated into 5mL BF839 medium at a 2% inoculation amount, and Lactobacillus rhamnosus GG (LGG, CICC6141, China Industrial Microbiological Culture Collection Management Center) was used as a positive control. All strains were cultured anaerobically in BF839 medium at 37°C for 24h. Sample processing: 0.5mL of culture solution was centrifuged at 12000rpm for 20min, the supernatant was discarded, and the extract (pre-cooled) in 0.5mL of strain total antioxidant capacity detection kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC1315) was resuspended; transferred to a sterilized screw cap tube containing beads (Sigma-Aldrich, G4649-1KG), and the wall was broken once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), and then centrifuged at 12000rpm and 4°C for 10min, and the supernatant was placed on ice for testing. The BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect BCA samples according to the instructions of the kit. The total antioxidant capacity detection kit of the strain was used to determine the antioxidant capacity of the sample in accordance with the instructions of the kit and combined with the standard curve. The total antioxidant capacity unit is μmol / mg prot. Experimental results: Figure 2 It can be seen that the total antioxidant capacity of Bifidobacterium bifidum Bbifi-1 reached 0.240±0.149μmol / mg prot, which is comparable to the positive control strain LGG, indicating that Bbifi-1 has antioxidant capacity in vitro.

[0083] Example 6: Antibacterial ability of Bifidobacterium bifidum Bbifi-1 against pathogenic bacteria

[0084] Seven common pathogenic bacteria that can cause diarrhea were selected for antibacterial ability testing. The source information of the pathogenic strains is as follows: Pseudomonas aeruginosa (CMCC(B)10104), purchased from China Food and Drug Inspection Institutes. Shigella (CMCC(B)51252), purchased from China Food and Drug Inspection Institutes. Escherichia coli (CMCC(B)44102), purchased from China Food and Drug Inspection Institutes. Salmonella paratyphi B (CMCC(B)50094), purchased from China Food and Drug Inspection Institutes. Yersinia enterocolitica CMCC(B)52204, purchased from China Food and Drug Inspection Institutes. Vibrio parahaemolyticus (ATCC 17802), purchased from American Microbiological Culture Collection. Clostridium difficile (CICC 22951), purchased from China Industrial Microbiological Culture Collection Administration Center.

[0085] Preparation of Bifidobacterium bifidum fermentation broth: After activation, Bifidobacterium bifidum Bbifi-1 was inoculated in a three-mixed liquid medium at a 2% inoculation rate, and anaerobically cultured at 37°C for 48 hours to obtain a fermentation broth. Preparation and coating of pathogenic bacteria: Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica and Vibrio parahaemolyticus are aerobic bacteria. After activation with TSB broth medium, they were diluted 50 times in TSB broth medium to reach a suitable concentration, and 0.2 mL of the diluted bacterial solution was coated on TSA solid medium. Clostridium difficile is an anaerobic bacterium. After anaerobic activation and transfer, it was diluted 50 times in a three-mixed liquid medium, and 0.2 mL of the diluted bacterial solution was coated on an anaerobic GAM solid medium (added with 5% horse serum, Beijing Solebold Technology Co., Ltd., S9050). Co-cultivation of Bifidobacterium bifidum and pathogens: Place 3 sterilized Oxford cups on the coated pathogen plate, add 0.2mL of Bifidobacterium bifidum fermentation liquid to the Oxford cups. Place in a culture box (anaerobic pathogens plus anaerobic gas production bag), place the plate upright for 24 hours, measure the size of the inhibition zone with a vernier caliper, and calculate the average value. Figure 3 As shown: Bifidobacterium bifidum Bbifi-1 has antibacterial ability against Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile.

[0086] Example 7: In vitro cell inflammation inhibition test of Bifidobacterium bifidum Bbifi-1

[0087] THP-1 cell polarization: THP-1 (Shangcheng Beina Chuanglian Biotechnology Co., Ltd., BNCC No. 358410) is a suspension cell. PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich Company, P1585) was used to induce THP-1 to polarize into mature macrophages. On this basis, LPS (Sigma-Aldrich Company, L3024) and IFN-γ (Peprotech, AF-30-02) were further used to induce mature macrophages to polarize into inflammatory macrophages. THP-1 cells were cultured at 1×10 5After inoculation at a density of 100 cells / well in a 96-well plate and overnight culture, 100 ng / mL PMA was added and placed in a 5% CO2 incubator. After culturing at 37°C for 24 hours, RPMI-1640 medium (ThermoFisher, C11875500BT) containing 10% FBS (Thermo Fisher, SH30084.03) and a final concentration of 100 ng / mL LPS and 20 ng / mL IFN-γ was replaced and placed in a 5% CO2 incubator for 24 hours at 37°C. Strain culture: 200 μL of Bifidobacterium bifidum Bbifi-1 bacterial solution was inoculated from the bacterial storage into 5 mL of the second mixed culture medium and anaerobically cultured in a 37°C electric thermostatic incubator for 24 hours. After transferring once, anaerobically culture for 8 hours. Take 1 mL of bacterial solution and centrifuge at 5000 rpm / min for 15 minutes. Resuspend the cells in RPMI-1640 medium containing 10% FBS to a volume of 5 × 10 7 CFU / mL for future use. Effect of Bifidobacterium bifidum Bbifi-1 on the expression of TNF-α in THP-1 cells: Mature THP-1 cells polarized by PMA were added with 100 μL of RPMI-1640 medium containing 10% FBS as the normal control group; inflammatory THP-1 cells (added with 100 μL of LPS with a final concentration of 100 ng / mL and 20 ng / mL IFN-γ) were used as the model control group; inflammatory THP-1 cells were added with 100 μL of dexamethasone (Sigma-Aldrich Company, D4902-25) solution with a final concentration of 25 μg / mL as the positive control group; the Bbifi-1 experimental group was added with 100 μL of the previously prepared Bbifidobacterium bifidum Bbifi-1 bacterial solution. Each group was placed in a 5% CO2 incubator and cultured at 37°C for 24 hours. 80 μL of cell culture medium was aspirated, centrifuged at 4°C, 5000 rpm / min for 15 min, the supernatant was collected, and the TNF-α content was detected using a Human TNF-α (Tumor Necrosis Factor Alpha) ELISA kit (Wuhan Elarite Biotechnology Co., Ltd., E-EL-H0109c).

[0088] Experimental results: Figure 4 As shown, the expression of TNF-α in the model control group was significantly higher than that in the normal control group (P<0.01); dexamethasone in the positive control group could significantly inhibit the expression of the proinflammatory factor TNF-α in THP-1 cells (P<0.01); Bifidobacterium bifidum Bbifi-1 could also significantly reduce the expression of the proinflammatory factor TNF-α (P<0.01), indicating that the strain has a significant anti-inflammatory effect in vitro.

[0089] Example 8: Therapeutic effect of Bifidobacterium bifidum Bbifi-1 on 5-fluorouracil (5-FU)-induced diarrhea in mice

[0090] Preparation of freeze-dried protective agent: Liquid A: 6g sucrose, 6g trehalose, 2g xylitol, 2g sorbitol, 44g purified water, sterilized at 115℃ for 30min; Liquid B: 2g arginine hydrochloride, 2g sodium glutamate, 16g purified water, sterilized at 115℃ for 30min; Liquid C: 4g sodium vitamin C, 16g purified water. Filter and sterilize for use. When using, mix according to the volume ratio of A:B:C=6:2:2. Preparation of bacterial powder: Inoculate the preserved Bifidobacterium bifidum Bbifi-1 into the bacterial powder preparation fermentation medium at a 10% inoculation rate, and culture anaerobically at 37℃, 90rpm for 15-20h to obtain the primary seed liquid (OD 600 Then, the inoculation amount of 1.5% was transferred to the bacterial powder to prepare the fermentation medium, and anaerobically cultured at 37°C and 90rpm for 8-10h to obtain the secondary seed solution (OD 600 The secondary seeds were inoculated at 3.0% with a peristaltic pump into a fermentation tank containing bacterial powder and fermentation medium, and the fermentation parameters (temperature 37°C, pH=5.1, speed 100rpm, pressure control 0.06MPa) were set to start fermentation. 600 Value ≥1.5 or OD 600 When the value increases by ≤0.1, stop fermentation and collect the bacterial liquid. Divide the bacterial liquid into centrifuge buckets, centrifuge and discard the supernatant. Add lyophilization protective agent at a weight ratio of 1:1 to 1:2 to emulsify the bacterial mud. Place the emulsified bacterial suspension on the plate layer of a freeze dryer cooled to -40°C for freeze drying. After the freeze drying process is completed, take out the bacterial cake and crush it to obtain bacterial powder. Before administering the drug to the animals, use 0.2mL of normal saline to mix 1×10 9 CFU bacterial powder was prepared into bacterial suspension. Experimental animals: 20 SPF grade male Balb / c mice (purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.), weighing 18-22g, were raised in an SPF grade animal room.

[0091] Experimental design: 5-FU (5-fluorouracil, purchased from Tianjin Jinyao Pharmaceutical Co., Ltd., specification 10mL / vial, 0.25g / 10mL) solution was used to induce chemotherapy-related diarrhea model in mice. The mice were randomly divided into 4 groups according to their initial body weight, namely normal control group, model control group, positive control group and Bifidobacterium bifidum Bbifi-1 group, with 5 mice in each group. Except for the normal control group, which was intraperitoneally injected with normal saline, other groups were treated with a single intraperitoneal injection of 5-FU for modeling, and the modeling dose was 350mg / kg (body weight). All groups were administered by gavage, and the normal control group and the model control group were gavaged with lyophilized protective agent; the positive control group was gavaged with 5mg / kg (body weight) loperamide (purchased from Xi'an Janssen Pharmaceutical Co., Ltd.) for 9 days; the Bifidobacterium bifidum Bbifi-1 group was gavaged with 1×10 9 CFU Bifidobacterium bifidum for 5 days. The overall experimental period was 9 days, recorded as D1 to D9. D1-D5 were administered by gavage for 5 days, D3 was treated with 5-FU single modeling, and after the end of D5 administration, it was observed for 4 consecutive days. The specific experimental groups and dosing regimens are shown in Table 1.

[0092] Table 1. Experimental groups and dosing regimens of Bifidobacterium bifidum Bbifi-1 in treating 5-FU-induced diarrhea in mice

[0093]

[0094] Note: 5-FU: 5-fluorouracil; CFU: colony forming unit; d: day

[0095] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.

[0096] Test results: Figure 5 As shown in the figure, compared with the model control group, the Bifidobacterium bifidum Bbifi-1 administration group had a significant improvement effect on 5-FU-induced diarrhea, and the effect was comparable to that of the positive drug loperamide ( Figure 5 A); both loperamide and Bifidobacterium bifidum Bbifi-1 could significantly reduce the total score of diarrhea (P<0.05) ( Figure 5B). In summary, Bifidobacterium bifidum Bbifi-1 has a significant therapeutic effect on 5-FU-induced diarrhea in mice. In order to compare the efficacy of Bifidobacterium bifidum Bbifi-1 and the standard strain of Bifidobacterium bifidum DSM20456 (purchased from the German Collection of Microorganisms and Cell Cultures), a CID model was constructed in the above manner. Previous data showed that stable diarrhea can occur in the CID model 4 days after D7, so the overall experimental period of this experiment was 7 days, recorded as D1-D7. On D3, except for the normal control group injected with normal saline intraperitoneally, other groups were treated with a single intraperitoneal injection of 5-FU for modeling. The modeling dose was 350 mg / kg (body weight). The Bbifi-1 group and the DSM20456 group were gavaged with 1×10 9 CFU, normal control group and model control group were gavaged with normal saline every day. During the experimental period, the feces of mice were observed and scored every day, and the scoring criteria were consistent with the previous ones. The experimental results are expressed as Mean±SEM, and One-way ANOVA was used for multiple comparison analysis. "*" indicates p<0.05 compared with the model control group, "**" indicates p<0.01 compared with the model control group, and "***" indicates p<0.001 compared with the model control group. The specific scheme is shown in Table 2.

[0097] Table 2. Experimental groups and dosing regimen for treating 5-FU-induced diarrhea in mice

[0098]

[0099] The test results are as follows Figure 6 As shown, compared with the model control group, Bbifi-1 was better than the standard strain DSM20456 in improving diarrhea caused by 5-FU.

[0100] Example 9: Therapeutic effect of Bifidobacterium bifidum Bbifi-1 on radiation enteritis model mice

[0101] The preparation methods of freeze-dried protective agent and bacterial powder are the same as those in Example 8. Experimental animals: 20 SPF-grade male C57BL / 6J mice, weighing 20-25 g, purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd., and raised in an SPF-grade animal room.

[0102] Experimental design: Radioactive enteritis mouse model was induced by abdominal X-ray irradiation. Mice were randomly divided into 4 groups according to their initial body weight, namely normal control group, model control group, positive control group (LGG) and Bifidobacterium bifidum Bbifi-1 group, with 5 mice in each group. Except for the normal control group, which was not irradiated, other groups were subjected to single abdominal X-ray irradiation modeling with a modeling dose of 11.5Gy. All groups were given drugs by gavage. The normal control group and the model control group were gavaged with normal saline; the positive control group was gavaged with 1×10 9CFU of Lactobacillus rhamnosus GG strain (LGG); Bifidobacterium bifidum Bbifi-1 group was intragastrically administered with 1×10 9 CFU Bifidobacterium bifidum. The overall experimental period was 13 days, recorded as D-2 to D10. The mice were given drugs by gavage for 12 consecutive days from D-2 to D9, and the abdomen of the mice was irradiated with X-rays once on D0 (day 3).

[0103] Diarrhea observation and scoring: Place mice in a mouse cage lined with clean filter paper, one per cage. Hard stools and normal stools are scored as 0 points; mild, slightly wet stools or soft stools are scored as 1 point; moderate, wet stools, unformed stools and unclean perianal area are scored as 2 points; severe, loose stools and severe unclean perianal area are scored as 3 points. During the experimental period, the feces of mice were observed and scored every day. The total diarrhea score was the sum of the daily diarrhea scores.

[0104] On D10 (day 13), the experimental animals were euthanized by sodium pentobarbital anesthesia and then subjected to gross dissection and anatomical observation. The specific experimental groups and drug administration schemes are shown in Table 3.

[0105] Table 3. Grouping and dosing regimen of the experiment on the treatment of X-ray-induced diarrhea in mice with Bifidobacterium bifidum Bbifi-1

[0106]

[0107] Note: CFU: colony forming unit; d: day

[0108] Test results: Figure 7 As shown in the results, compared with the model control group, Bifidobacterium bifidum Bbifi-1 had a significant improvement effect on X-ray irradiation-induced diarrhea, and the effect was comparable to that of the positive control group LGG ( Figure 7 A); LGG and Bifidobacterium bifidum Bbifi-1 could significantly reduce the total score of diarrhea (P<0.05, Figure 7 B). The above results indicate that Bifidobacterium bifidum Bbifi-1 has a significant improvement effect on X-ray irradiation-induced diarrhea in mice.

[0109] Example 10: Detection of total antioxidant capacity of Bifidobacterium bifidum Bbifi-1 lysate

[0110] The preserved Bifidobacterium bifidum Bbifi-1 was activated and inoculated into a three-mixed liquid culture medium. A lactic acid bacteria product (Chemisches Laboratorium Dr. Kurt Richter GmbH, 3231803), bifid yeast (Shanghai Yanfu Industrial Co., Ltd.) and a standard strain of Bifidobacterium bifidum (DSM20456, German Collection of Microorganisms and Cell Cultures) were used as positive controls. Both Bifidobacterium bifidum Bbifi-1 and the standard strain of Bifidobacterium bifidum DSM20456 were anaerobically cultured in the three-mixed liquid culture medium at 37°C for 24 h. Sample processing: Take 0.5mL of culture solution of Bifidobacterium bifidum Bbifi-1 and Bifidobacterium bifidum standard strain DSM20456 respectively, centrifuge at 12000rpm for 20min, discard the supernatant, resuspend with 0.5mL of extract solution (precooled) in strain total antioxidant capacity detection kit (kit purchased from Beijing Solebow Technology Co., Ltd., BC1315); transfer to a sterilized screw cap tube containing beads (Sigma-Aldrich, USA, G4649-1KG), shake once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), centrifuge at 12000rpm at 4℃ for 10min, take the supernatant and place it on ice for testing. Lactic acid bacteria products and bifid yeast are directly centrifuged at 12000rpm at 4℃ for 10min, take the supernatant and place it on ice for testing. The BCA protein concentration determination kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., PC0020) was used to draw a standard curve and detect BCA samples according to the instructions of the kit. The total antioxidant capacity detection kit of the strain was used to determine the antioxidant capacity of the sample in accordance with the instructions of the kit and combined with the standard curve. The unit of total antioxidant capacity is μmol / mg prot. Data processing: Three parallel control groups were set up in this experiment. The results are expressed as Mean±SD. One-way ANOVA was used for multiple comparison analysis. *** indicates that compared with lactic acid bacteria products, p<0.001; ### indicates that compared with bifid yeast, p<0.001.

[0111] Experimental results: Figure 8 It can be seen that the total antioxidant capacity of Bifidobacterium bifidum Bbifi-1 reached 0.877±0.017μmol / mg prot, which is comparable to the standard strain of Bifidobacterium bifidum DSM20456, and significantly better than lactic acid bacteria products and bifid yeast (p<0.001), indicating that Bbifi-1 has significant antioxidant capacity in vitro.

[0112] Example 11: Detection of DPPH free radical scavenging ability of Bifidobacterium bifidum Bbifi-1 lysate

[0113] The preserved Bifidobacterium bifidum Bbifi-1 was activated and inoculated into a three-mixed liquid medium, and the bifidobacterium (Shanghai Yanfu Industrial Co., Ltd.) and the standard strain of Bifidobacterium bifidum (DSM20456, German Collection of Microorganisms and Cell Cultures) were used as positive controls. All strains were cultured anaerobically at 37°C for 24 hours in the three-mixed liquid medium. Sample processing: 0.5 mL of the culture solution was centrifuged at 12000 rpm for 20 minutes, the supernatant was discarded, and the sample was resuspended with 0.5 mL of the extract (pre-cooled) in the DPPH free radical scavenging ability detection kit (the kit was purchased from Beijing Solebold Technology Co., Ltd., BC4755); transferred to a sterilized screw-cap tube containing beads (Sigma-Aldrich, G4649-1KG), and the sample was shaken once with a rapid sample preparation instrument (parameter setting: 4.5 m / s, 30 seconds), and then centrifuged at 12000 rpm and 4°C for 10 minutes, and the supernatant was placed on ice for testing. The bifid yeast was directly centrifuged at 12000 rpm and 4°C for 10 min, and the supernatant was placed on ice for testing. The DPPH free radical scavenging ability test kit of the strain was used to measure the DPPH free radical scavenging ability of the sample according to the instructions of the kit.

[0114] Experimental results: Fig. 9 It can be seen that the DPPH free radical scavenging ability of Bbifi-1 lysate is 10.85%±1.44%, which is comparable to that of Bifida yeast and significantly better than that of the standard strain DSM20456 lysate (p<0.001), indicating that Bbifi-1 lysate has significant DPPH free radical scavenging ability in vitro. The calculation method is as follows:

[0115]

[0116] Data processing: Three parallel control groups were set up in this experiment. The results were expressed as Mean±SD. One-way ANOVA was used for multiple comparison analysis. $$$ means p<0.001 compared with the standard strain of Bifidobacterium bifidum DSM20456.

[0117] Example 12: Detection of ABTS free radical scavenging ability of Bifidobacterium bifidum Bbifi-1 lysate

[0118] The preserved Bifidobacterium bifidum Bbifi-1 was activated and inoculated into a three-mixed liquid culture medium. A lactic acid bacteria product (Chemisches Laboratorium Dr. Kurt Richter GmbH, 3231803) and a standard strain of Bifidobacterium bifidum (DSM20456, German Collection of Microorganisms and Cell Cultures) were used as positive controls. All strains were anaerobically cultured in the three-mixed liquid culture medium at 37°C for 24 h. Sample processing: Take 0.5mL of culture solution and centrifuge at 12000rpm for 20min, discard the supernatant, resuspend with 0.5mL of the extract (pre-cooled) in the ABTS free radical scavenging ability test kit (the kit was purchased from Beijing Solebow Technology Co., Ltd., BC4775); transfer to a sterilized screw cap tube containing beads (Sigma-Aldrich, G4649-1KG), shake once with a rapid sample preparation instrument (parameter setting: 4.5m / s, 30s), centrifuge at 12000rpm at 4℃ for 10min, take the supernatant and place it on ice for testing. Lactic acid bacteria products are directly centrifuged at 12000rpm at 4℃ for 10min, and the supernatant is taken and placed on ice for testing.

[0119] The ABTS free radical scavenging ability test kit of the strain was used to measure the ABTS free radical scavenging ability of the sample according to the instructions of the kit. The calculation method is as follows:

[0120]

[0121] Data processing: This experiment set up 3 parallel control groups, the results are expressed as Mean±SD, and one-way ANOVA was used for multiple comparison analysis. **, indicates that compared with lactic acid bacteria products, p<0.01; $$$, indicates that compared with the standard strain of Bifidobacterium bifidum DSM20456, p<0.001. Fig.10 It can be seen that the ABTS free radical scavenging ability of Bifidobacterium bifidum Bbifi-1 reached 28.20%±3.47%, which was significantly better than lactic acid bacteria products (p<0.01) and the standard strain DSM20456 lysate (p<0.001), indicating that Bbifi-1 lysate has significant ABTS free radical scavenging ability in vitro.

[0122] Example 13: Inhibitory effect of Bifidobacterium bifidum Bbifi-1 lysate on acne pathogens

[0123] Common acne pathogens were selected for antibacterial ability testing, and the source information of the pathogenic strains is shown in Table 4 below.

[0124] Table 4. Source information of pathogenic strains

[0125]

[0126] Preparation of strain culture: Bifidobacterium bifidum Bbifi-1 and Bifidobacterium bifidum standard strain DSM20456 (purchased from the German Collection of Microorganisms and Cell Cultures) were activated and inoculated into a three-mixed liquid medium at an inoculum rate of 4% (volume ratio), and cultured anaerobically at 37°C for 48 hours. The culture was transferred to a screw cap tube containing beads, broken at 4.5 m / s for 30 seconds, centrifuged at 6000 rpm for 10 minutes, and then filtered with a 0.22 μm filter head, and diluted 5 times with the three-mixed liquid medium to obtain Bbifi-1 lysate and DSM20456 lysate. Lactic acid bacteria products (manufacturer: Chemisches Laboratorium Dr. KurtRichter GmbH batch number: 3231803) and bifid yeast (manufacturer: Shanghai Yanfu Industrial Co., Ltd., INCI: bifid yeast fermentation product lysate) were diluted 5 times with the three-mixed liquid medium as product controls.

[0127] Preparation of pathogenic bacteria: Staphylococcus aureus was activated with TSB medium, Propionibacterium acnes was activated with three-mixed liquid medium, and then diluted in the corresponding culture medium to reach the appropriate concentration.

[0128] Co-culture with pathogenic bacteria: 0.1 mL of lysate and 0.1 mL of pathogenic bacteria were placed in a 96-well plate in the experimental group, and the three groups were parallel; 0.1 mL of product and 0.1 mL of pathogenic bacteria were placed in a 96-well plate in the product control group, and the three groups were parallel; 0.1 mL of pathogenic bacteria and 0.1 mL of corresponding culture medium were placed in a 96-well plate in the pathogen positive control group, and the Staphylococcus aureus was cultured aerobically for 24 hours, and Propionibacterium acnes was cultured anaerobically for 24 hours, and the OD at 0h and 24h was detected 600 .

[0129] Data processing: Calculate the inhibition rate (R), the formula is R = (1-ΔOD1 / ΔOD0) × 100%, where ΔOD1 is the OD value of the experimental group before and after 24 hours of culture. 600 ΔOD0 is the OD value of the pathogenic bacteria positive control group before and after 24h of culture. 600 The results were expressed as Mean±SD of the inhibition rate, and One-way ANOVA was used for comparative analysis. The antibacterial ability of Bbifi-1 lysate was compared with that of lactic acid bacteria products, bifid yeast, and DSM20456 lysate. *** indicates a significant difference from lactic acid bacteria products, P<0.001; **** indicates a significant difference from lactic acid bacteria products, P<0.0001; ### indicates a significant difference from bifid yeast, P<0.001; $$ indicates a significant difference from DSM20456 lysate, P<0.01; $$$$ indicates a significant difference from DSM20456 lysate, P<0.0001.

[0130] Experimental results: Fig.11 As shown, Bbifi-1 lysate has antibacterial ability against Staphylococcus aureus and Propionibacterium acnes. Fig.11 The antibacterial ability of A against Staphylococcus aureus was significantly stronger than that of lactic acid bacteria products, bifid yeast and DSM20456 lysate (P<0.0001, P<0.001, P<0.0001, respectively); Fig.11 The antibacterial ability of B against Propionibacterium acnes was significantly stronger than that of lactic acid bacteria products and DSM20456 lysate (significance was P<0.001, P<0.01, respectively).

[0131] Example 14: In vitro cell inflammation inhibition effect of Bifidobacterium bifidum Bbifi-1 lysate

[0132] THP-1 cell polarization: RPMI-1640 (Thermo Fisher Scientific (China) Co., Ltd., C11875500BT) medium containing 10% FBS (Thermo Fisher Scientific (China) Co., Ltd., 16000-044) and PMA (phorbol 12-myristate 13-acetate, Sigma-Aldrich Company, P1585) at a final concentration of 100 ng / mL was used. 5 THP-1 cells were seeded in a 96-well plate at a seeding density of 10 cells / well and placed in a 5% CO2 incubator at 37°C for 24 h to polarize them into mature macrophages.

[0133] Preparation of strain culture samples: Bifidobacterium bifidum Bbifi-1 and Bifidobacterium bifidum standard strain DSM20456 (purchased from the German Collection of Microorganisms and Cell Cultures) were activated and inoculated into a three-mixed liquid medium and cultured anaerobically at 37°C for 48h. RPMI-1640 medium containing 10% FBS, a final concentration of 100ng / mL LPS (Sigma-Aldrich Company, L3024) and 20ng / mL IFN-γ (PeproTech, AF-300-02) was prepared as a premix for inflammatory stimulation. After high-pressure steam sterilization (121°C, 20min), the strain culture was filtered with a 0.22μm filter head and diluted 10 times with the above premix to obtain an inactivated lysate sample.

[0134] Effect of Bifidobacterium bifidum Bbifi-1 on IL-6 expression in THP-1 cells: This experiment was divided into 6 groups, including normal control group, model control group, dexamethasone group, lactic acid bacteria product, DSM20456 lysate, and Bbifi-1 lysate. After THP-1 was polarized into mature macrophages, the normal control group was replaced with RPMI-1640 medium containing 10% FBS; the model control group was replaced with the above-prepared RPMI-1640 medium premix containing 10% FBS, a final concentration of 100 ng / mL LPS (Sigma-Aldrich Company, L3024) and 20 ng / mL IFN-γ (PeproTech, AF-300-02) for inflammatory stimulation. The dexamethasone group was replaced with the above premix containing a final concentration of 25 μg / mL dexamethasone (purchased from Sigma-Aldrich Company, D4902-25). Lactic acid bacteria product (ProRenew Complex CLR TM , CLR Berlin) replaced the above premix containing 3% lactic acid bacteria, and the other groups replaced the inactivated lysate samples prepared earlier. The cell culture plate was placed in a 5% CO2 incubator. After culturing at 37°C for 36 h, 160 μL of cell culture medium was aspirated from each group, centrifuged at 4°C, 1000 rpm / min for 20 min, and the supernatant was collected. The IL-6 content was detected using Human IL-6 (Interleukin 6) ELISA kit (purchased from Wuhan Elaruite Biotechnology Co., Ltd., E-EL-H6156). Three parallel control groups were set up in this experiment. The results are expressed as Mean±SD, and One-way ANOVA was used for multiple comparison analysis. *, compared with the model group, p<0.05; **, compared with the model group, p<0.01; ***, compared with the model group, p<0.001; $$$, compared with the standard strain of Bifidobacterium bifidum DSM20456, p<0.001.

[0135] Experimental results: Fig.12 As shown, the expression of IL-6 in the cell supernatant of the model control group was significantly higher than that of the normal control group (P<0.001); the dexamethasone group could significantly inhibit the expression of the proinflammatory factor IL-6 in THP-1 cells (P<0.001); compared with the model control group, the lysate of Bifidobacterium bifidum Bbifi-1 could significantly reduce the expression of the proinflammatory factor IL-6 (P<0.001), and its lysate had better anti-inflammatory effect than the standard strain of Bifidobacterium bifidum DSM20456, indicating that the lysate of Bifidobacterium bifidum Bbifi-1 has a certain anti-inflammatory effect in vitro.

[0136] Example 15: Experiment on the inhibition of oil secretion of SZ95 cells by Bifidobacterium bifidum Bbifi-1 using oil red-O staining

[0137] Strain culture: Bifidobacterium bifidum Bbifi-1 and Bifidobacterium bifidum standard strain DSM20456 (purchased from the German Collection of Microorganisms and Cell Cultures) were activated and inoculated into a three-mixed liquid medium and cultured anaerobically in a 37°C electric constant temperature incubator for 48 h. DMEM (Thermo Fisher Scientific, C11995500BT) medium containing 10% FBS (Thermo Fisher Scientific, 16000-044) and a final concentration of 100 μM oleic acid (MedChemexpress Biotechnology, HY-N1446, USA) was prepared as a premix for model construction.

[0138] Cell inoculation: SZ95 cells with good growth status and appropriate density (Qingqi (Shanghai) Biotechnology Development Co., Ltd., BFN60807569) were digested with trypsin (Beijing Lanjieke Technology Co., Ltd., BL501A), collected by centrifugation, and diluted to 10 with DMEM complete medium containing 10% FBS and 1% PS (Thermo Fisher Scientific, 15140-122). 5 The cells were inoculated into 24-well plates with a volume of 1 mL per well and placed in a 5% CO2 incubator at 37°C for 24 h.

[0139] Construction and administration of SZ95 cell model: The experiment was divided into normal control group, model control group, positive control group (salicylic acid, isotretinoin) and experimental group. The treatment methods of different groups were as follows: the normal control group was added with DMEM medium containing 10% FBS, the model control group was added with the above premixed solution of DMEM medium containing 10% FBS and a final concentration of 100 μM oleic acid, the positive control group (salicylic acid) was added with the above premixed solution containing 20 μg / mL salicylic acid (Beijing Solebold Technology Co., Ltd., S7080), the positive control group (isotretinoin) was added with the above premixed solution containing 100 μM isotretinoin (MedChemexpress Biotechnology Co., Ltd., USA, HY-15127), and the experimental groups were added with live bacterial samples diluted with the above premixed solution, and the concentration was 10 after counting under a microscope. 8 Place in a 5% carbon dioxide incubator and culture at 37°C for 24 hours.

[0140] SZ95 cell staining treatment: discard the cell supernatant, wash twice with sterile PBS (Wuhan Boster Biotechnology Co., Ltd., PYG0021), add 4% paraformaldehyde (Beijing Lanjieke Technology Co., Ltd., BL539A) to fix for 30 minutes, wash twice with sterile PBS, add 60% isopropanol (Sangon Biotechnology (Shanghai) Co., Ltd., A507048-0500) solution and let stand for 3 minutes, add Oil Red O dye solution (Beijing Solebold Technology Co., Ltd., G1260) for staining, add 60% isopropanol solution after staining to observe the cell gap under a microscope, the cell gap is clear, add sterile PBS to wash twice, observe under a microscope, add isopropanol to dissolve the oil stained with Oil Red O solution, and measure the absorbance at 500nm using an enzyme reader.

[0141] Experimental results: Fig.13 As shown, compared with the model group, the Bbifi-1 group significantly reduced the lipid accumulation in SZ95 cells (p<0.001); compared with the positive control group (salicylic acid), the Bbifi-1 group was significantly better than salicylic acid in reducing the lipid accumulation in SZ95 cells (P<0.001). Compared with the positive control group (isotretinoin), the Bbifi-1 group was significantly better than isotretinoin in reducing the lipid accumulation in SZ95 cells (P<0.05). The results are expressed as Mean±SD, and one-way ANOVA was used for multiple comparison analysis. ***, compared with the model group, p<0.001; ###, compared with the positive control group (salicylic acid), p<0.001; &, compared with the positive control group (isotretinoin), p<0.05.

[0142] It is known from common technical knowledge that the present invention can be implemented by other embodiments that do not deviate from its spirit or essential features. Therefore, the above disclosed embodiments are only illustrative in all respects and are not exclusive. All changes within the scope of the present invention or within the scope equivalent to the present invention are included in the present invention.

Claims

1. A biomaterial, wherein the biomaterial is selected from the following M1, M2, M3 and M4; M1: Bifidobacterium bifidum or its lysate with microbial deposit number of CCTCC NO: M2023349; M2: progeny strain of Bifidobacterium bifidum with microbial deposit number CCTCC NO: M2023349 or its lysate; M3: a cloned strain of Bifidobacterium bifidum with a microbial deposit number of CCTCC NO: M2023349 or a lysate thereof; M4: Pure culture of Bifidobacterium bifidum with the microorganism deposit number of CCTCC NO: M2023349 or its lysate.

2. A method for culturing Bifidobacterium bifidum, the method comprising: inoculating Bifidobacterium bifidum with a microbiological preservation number of CCTCC NO: M2023349, a progeny strain of Bifidobacterium bifidum with a microbiological preservation number of CCTCC NO: M2023349, a cloned strain of Bifidobacterium bifidum with a microbiological preservation number of CCTCC NO: M2023349, or a pure culture of Bifidobacterium bifidum with a microbiological preservation number of CCTCC NO: M2023349 into a culture medium, performing proliferation culture, and obtaining proliferated Bifidobacterium bifidum.

3. A composition comprising the biomaterial according to claim 1 as an active material.

4. The composition according to claim 3, characterized in that The composition further contains auxiliary materials.

5. The composition according to claim 4, characterized in that The auxiliary material is selected from any one of the following materials: Bacterial culture medium; Lyoprotectants; Pharmaceutically acceptable carriers or excipients; Acceptable materials in health products; acceptable materials in cosmetics; Materials acceptable in food.

6. Use of the biomaterial according to claim 1 or the composition according to any one of claims 3 to 5 in the preparation of a product for use alone or in combination with other microbial agents and / or drugs to improve the health of a subject; The improving the health condition of the subject is selected from: Treat, prevent and / or relieve chemotherapy-induced diarrhea; Treat, prevent and / or alleviate the side effects of radiation therapy; Inhibiting the proliferation of any one, any two, any three, any four, any five, any six, any seven or eight of Staphylococcus aureus, Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile in the body cavity of the subject; Treat, prevent and / or slow down tissue damage, disease or sub-health condition caused by any one, any two, any three, any four, any five, any six, any seven or eight of Staphylococcus aureus, Pseudomonas aeruginosa, Shigella, Escherichia coli, Salmonella paratyphi B, Yersinia enterocolitica, Vibrio parahaemolyticus and Clostridium difficile; Treat, prevent and / or alleviate diseases or sub-health conditions caused by Propionibacterium acnes; Treat, prevent and / or relieve acne; Treating, preventing and / or alleviating tissue damage, disease or sub-health condition caused by increased expression of any one, any two or three of IFN-γ, TNF-α and IL-6; Scavenges DPPH free radicals and / or ABTS free radicals; Improve the antioxidant capacity in the intestines of the subjects; Improves cell oil accumulation.

7. The use according to claim 6, characterized in that The subject is selected from humans and mice. Preferably, the product is selected from medicines, health products, foods and cosmetics.

8. The use according to claim 6, characterized in that The side effect caused by the radiotherapy is radiation enteritis.

9. The use according to claim 6, characterized in that The chemotherapy drugs are selected from fluorouracil chemotherapy drugs, taxane chemotherapy drugs, platinum chemotherapy drugs, topoisomerase I inhibitors, and tyrosine kinase inhibitors.

10. The use according to claim 9, characterized in that The chemotherapy drug is selected from doxorubicin, epirubicin, dactinomycin D, doxorubicin, daunorubicin, paclitaxel, docetaxel, cisplatin, carboplatin, lobaplatin, cyclophosphamide, nitrogen mustard, carmustine, camptothecin, hydroxycamptothecin, topotecan, capecitabine, gemcitabine, methotrexate, pemetrexed, cytarabine, 5-fluorouracil, and irinotecan.

Citation Information

Cited By

  • Specific primer for detecting bifidobacterium bifidum and application thereof

    CN118995972A

  • Lactobacillus polyactis composition for improving skin as well as derivative and application of lactobacillus polyactis composition

    CN119530100A

  • Bifidobacterium bifidum SX-P824 and application of bifidobacterium bifidum SX-P824 in preparation of lipid-lowering and / or antioxidant products

    CN119799601A

  • Bifidobacterium bifidum and application thereof in ophthalmic products or intestinal flora regulating products

    CN120944788A

  • Bifidobacterium bifidum and application thereof in ophthalmic products or products for regulating intestinal flora

    CN120944788B